GlaxoSmithKline plc (GSK) Holdings Lifted by San Francisco Sentry Investment Group CA

San Francisco Sentry Investment Group CA grew its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 110.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,749 shares of the pharmaceutical company’s stock after purchasing an additional 4,589 shares during the quarter. San Francisco Sentry Investment Group CA’s holdings in GlaxoSmithKline were worth $356,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of GSK. 1st Global Advisors Inc. increased its holdings in shares of GlaxoSmithKline by 0.4% during the 2nd quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock worth $227,000 after acquiring an additional 19 shares during the last quarter. King Luther Capital Management Corp increased its holdings in shares of GlaxoSmithKline by 1.0% during the 2nd quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock worth $234,000 after acquiring an additional 55 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in shares of GlaxoSmithKline by 1.9% during the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after acquiring an additional 64 shares during the last quarter. Strategic Global Advisors LLC increased its holdings in shares of GlaxoSmithKline by 0.6% during the 2nd quarter. Strategic Global Advisors LLC now owns 12,179 shares of the pharmaceutical company’s stock worth $525,000 after acquiring an additional 75 shares during the last quarter. Finally, PagnatoKarp Partners LLC increased its holdings in shares of GlaxoSmithKline by 1.4% during the 2nd quarter. PagnatoKarp Partners LLC now owns 5,812 shares of the pharmaceutical company’s stock worth $253,000 after acquiring an additional 80 shares during the last quarter. 9.83% of the stock is currently owned by hedge funds and other institutional investors.

Shares of GlaxoSmithKline plc (GSK) opened at $35.32 on Friday. The firm has a market capitalization of $86,863.92, a price-to-earnings ratio of 12.52, a PEG ratio of 1.96 and a beta of 0.98. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. GlaxoSmithKline plc has a 1 year low of $34.72 and a 1 year high of $44.53.

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be given a dividend of $0.5037 per share. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.70%. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date is Thursday, November 9th. GlaxoSmithKline’s dividend payout ratio is presently 163.12%.

In related news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 10.00% of the company’s stock.

A number of research analysts have commented on the company. Argus decreased their price objective on GlaxoSmithKline to $40.00 and set a “buy” rating on the stock in a report on Thursday. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Thursday, September 21st. UBS raised GlaxoSmithKline from a “neutral” rating to a “buy” rating and upped their price objective for the company from $35.04 to $35.85 in a report on Monday, November 27th. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Finally, Investec lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Monday, November 6th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the company’s stock. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus price target of $39.71.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline plc (GSK) Holdings Lifted by San Francisco Sentry Investment Group CA” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.com-unik.info/2017/12/03/glaxosmithkline-plc-gsk-holdings-lifted-by-san-francisco-sentry-investment-group-ca.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit